Outsourced Pharma White Papers

  1. Unlocking Durable Allogeneic Cell Therapy 5/13/2026

    Advances in genome engineering and immune evasion are enabling scalable, durable allogeneic cell therapies, overcoming rejection challenges and expanding potential treatments across diverse diseases.

  2. Smart Scaling For Cell And Gene Therapies 2/5/2026

    To meet patient demand, advanced therapy manufacturing processes must be commercial ready. CGT sponsors can mitigate risk and protect viability by partnering with a CDMO that prioritizes scalability.

  3. Engineering Reliability In Cell Therapy Manufacturing 2/3/2026

    A cell therapy manufacturing model built on precision planning, digital execution, lifecycle‑ready CMC systems, and transparent collaboration to achieve high reliability and reduce variability across programs.

  4. Unlocking The Potential Of Biocatalysis 1/22/2026

    Biocatalysis delivers cleaner, more selective pharma processes while cutting energy use and waste. Engineered enzymes broaden their reach, enabling faster development and greater sustainability.

  5. Annex 1: Sterile Fill/Finish For Early Phase Clinical Supplies 5/5/2025

    Meeting stringent requirements for sterile fill/finish operations hinges on robust contamination control strategies, advanced isolator technology, and rigorous integrity testing to ensure patient safety.

  6. IP Considerations In Drug Development For Biotech Companies 4/20/2026

    Integrate a strategic intellectual property approach early in drug development to streamline research, uncover opportunities, and maximize the return on your investment.

  7. Understanding And Implementing USP <665> For Single-Use Systems 4/14/2026

    New expectations for single-use systems require structured risk assessment and extractables testing. As compliance deadlines near, practical guidance aligns science, knowledge, regulatory readiness.

  8. Key Selection Criteria For Cell & Gene Therapy CDMOs 3/4/2026

    Choosing the right CDMO requires early internal assessment plus strong technical capability, agility, advocacy, clear communication, and long‑term alignment to meet evolving cell and gene therapy needs.

  9. Challenges And Solutions In Lyophilization Development For ADCs 12/10/2025

    Successful ADC lyophilization requires a robust, individualized process driven by thermal characterization using DSC and FDM to define the critical parameters for stability and efficient manufacturing.

  10. Circular Single-Stranded Cell-Free DNA For Next-Gen Gene Editing 3/16/2026

    Next‑gen circular DNA payloads enhance gene insertion by improving stability, lowering cytotoxicity, and enabling precise, scalable integration across HDR, recombination, and transposition systems.